- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06558825
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women With Trauma-related Conditions
Entwicklung und Pilottest einer klinikbasierten PrEP-Aufnahme- und Adhärenzintervention für Frauen bei der Behandlung traumabedingter Erkrankungen
The investigators have previously developed an integrated bio-behavioral intervention to promote PrEP uptake and adherence in cisgender women who are undergoing treatment for trauma-related mental health conditions and who are at a higher risk for HIV. The intervention is delivered within the mental health treatment setting and integrates knowledge, behavioral skills, and motivation to engage in and adhere to PrEP care. The purpose of this study is to assess the preliminary efficacy, feasibility, and acceptability of this intervention. The hypothesis is that, compared to standard treatment, the intervention will be feasible, acceptable, and associated with greater PrEP uptake and adherence.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The new integrated intervention will include motivational counseling guided by the Information Motivation-Behavioral Skills Model (IMB) which seeks to influence behavior change via information sharing, increasing motivation for change, and teaching behavioral skills to increase self-efficacy. This novel intervention will be delivered remotely using the emocha Mobile Health smartphone application. We expect that, compared to standard SUD treatment only, the integrated intervention will be associated with higher rates of PrEP uptake and adherence.This study will 1) Collect information on knowledge and attitudes about PrEP use and obtain feedback about the potential design of the integrated behavioral intervention from women undergoing treatment for trauma-related conditions who are at risk for HIV and their providers; 2) Develop an integrated behavioral intervention to promote PrEP uptake and adherence in women undergoing treatment for trauma-related conditions who are at high risk for HIV, and 3) Assess feasibility, acceptability and initial efficacy of the intervention.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77054
- Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Currently undergoing mental health treatment;
- Have a history of trauma;
- HIV negative;
- Sexually active with an opposite sex partner within the past 6 months;
- Not using PrEP for HIV prevention at the time of screening;
- Eligible for PrEP based on having at least one Centers for Disease Control and Prevention (CDC)-defined criteria for PrEP;
- Fluent in English;
- Own or have regular access to a smart phone.
Exclusion Criteria:
- HIV positive;
- Concurrently participating in another HIV prevention program;
- Have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy;
- Have psychological distress that would prohibit them from participating in the study;
- Be unable or unwilling to meet study requirements.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Integrierte Intervention zur Förderung der PrEP-Aufnahme
|
Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting. |
|
Aktiver Komparator: Standardbehandlungsbedingung
|
Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants who uptake PrEP
Zeitfenster: 12 weeks post intervention
|
PrEP uptake is defined as obtaining a prescription and taking the first dose. |
12 weeks post intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Durchführbarkeit der Intervention anhand der Anzahl der von den Teilnehmern besuchten Sitzungen
Zeitfenster: 15 Wochen nach der Einschreibung
|
15 Wochen nach der Einschreibung
|
|
|
Number of Participants who adhere to PrEP
Zeitfenster: 12 weeks post PrEP initiation
|
PrEP adherence is lab confirmed and is defined as having adequate levels of tenofovir (TFV) (>1000ng/ml). |
12 weeks post PrEP initiation
|
|
PrEP adherence as assessed by proportion of videos uploaded
Zeitfenster: from the time of PrEP initiation to 12 weeks post PrEP initiation
|
In the intervention arm, participants are asked to take a video of themselves taking PrEP. Videos are uploaded through an app, which is offered in the intervention arm only (and not the standard treatment arm). Data will be reported as the number of days a video is uploaded divided by the number of days of the intervention period. |
from the time of PrEP initiation to 12 weeks post PrEP initiation
|
|
PrEP adherence as assessed by proportion of self-reported daily adherence
Zeitfenster: from the time of PrEP initiation to 12 weeks post PrEP initiation
|
In both arms, participants are sent a questionnaires weekly in which they record the number of days they took PrEP over the past seven days. Data will be reported as the number of days PrEP is taken divided by the number of days of the intervention period. |
from the time of PrEP initiation to 12 weeks post PrEP initiation
|
|
Intervention feasibility as assessed by number of participants enrolled
Zeitfenster: at the time of enrollment
|
The number enrolled is the number of participants who signed the consent form. |
at the time of enrollment
|
|
Intervention feasibility as assessed by study retention
Zeitfenster: 15 weeks post enrollment
|
Study retention is assessed by the the number of participants who completed the study. |
15 weeks post enrollment
|
|
Intervention acceptability as assessed by score on a satisfaction questionnaire
Zeitfenster: 15 weeks post enrollment
|
This is a 15 item questionnaire and each item is scored from 1 (not at all true) to 9 (absolutely true). Total score ranges from 15 to 135, with a higher score indicating greater satisfaction. |
15 weeks post enrollment
|
|
Change in PrEP Anticipated Stigma as assessed by the PrEP Anticipated Stigma Scale
Zeitfenster: baseline, 15 weeks post enrollment
|
Total score ranges from 8 to 32, with a higher score indicating greater stigma. |
baseline, 15 weeks post enrollment
|
|
Change in perceived HIV risk as assessed by Perceived Risk of HIV Scale
Zeitfenster: baseline, 15 weeks post enrollment
|
Total score ranges from 10 to 40, with a higher score indicating a greater perceived HIV risk. |
baseline, 15 weeks post enrollment
|
|
Change in PrEP knowledge as assessed by PrEP Knowledge Questionnaire
Zeitfenster: baseline, 15 weeks post enrollment
|
Total score ranges from 0 to 6, with a higher score indicating a greater knowledge about PrEP. |
baseline, 15 weeks post enrollment
|
|
Change in PrEP attitudes as assessed by PrEP Attitudes Measure
Zeitfenster: baseline, 15 weeks post enrollment
|
Total score ranges from 5.2 to 26, with a higher score indicating a better attitude toward PrEP. |
baseline, 15 weeks post enrollment
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Angela Heads, PhD, The University of Texas Health Science Center, Houston
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HSC-MS-21-0544
- 1R34DA055496-01 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .